Aura Biosciences, Inc. Files 2023 Annual Report on Form 10-K

Ticker: AURA · Form: 10-K · Filed: 2024-03-27T00:00:00.000Z

Sentiment: neutral

Topics: 10-K, Aura Biosciences, Annual Report, Financial Instruments, Stock Compensation

TL;DR

<b>Aura Biosciences, Inc. has submitted its 2023 10-K filing, detailing business operations, financial instruments, and stock-related activities.</b>

AI Summary

Aura Biosciences, Inc. (AURA) filed a Annual Report (10-K) with the SEC on March 27, 2024. Aura Biosciences, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is engaged in the development of biological products, specifically excluding diagnostic substances, under SIC code 2836. Key dates and events related to various agreements and offerings, including the 'Two Thousand And Eighteen And Two Thousand Twenty' period, are referenced. The filing details financial instruments and fair value measurements, including US Government Agencies Debt Securities and Corporate Debt Securities as of December 31, 2022, and December 31, 2023. Various stock-based compensation plans and agreements are mentioned, such as the 'TwoThousandTwentyOneEmployeeStockPurchasePlan' and 'StockOptionsToPurchaseCommonStock'.

Why It Matters

For investors and stakeholders tracking Aura Biosciences, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Aura Biosciences' financial health, operational activities, and strategic initiatives for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed information on financial instruments, fair value measurements, and stock-based compensation plans offers insights into the company's financial management and its approach to employee incentives and capital raising.

Risk Assessment

Risk Level: medium — Aura Biosciences, Inc. shows moderate risk based on this filing. The filing is a standard 10-K, which is a comprehensive annual report, but lacks specific financial performance metrics like revenue or net income in the provided snippet, making a definitive risk assessment challenging without further details.

Analyst Insight

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to form a complete investment thesis.

Key Numbers

Key Players & Entities

FAQ

When did Aura Biosciences, Inc. file this 10-K?

Aura Biosciences, Inc. filed this Annual Report (10-K) with the SEC on March 27, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Aura Biosciences, Inc. (AURA).

Where can I read the original 10-K filing from Aura Biosciences, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Aura Biosciences, Inc..

What are the key takeaways from Aura Biosciences, Inc.'s 10-K?

Aura Biosciences, Inc. filed this 10-K on March 27, 2024. Key takeaways: Aura Biosciences, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The company is engaged in the development of biological products, specifically excluding diagnostic substances, under SIC code 2836.. Key dates and events related to various agreements and offerings, including the 'Two Thousand And Eighteen And Two Thousand Twenty' period, are referenced..

Is Aura Biosciences, Inc. a risky investment based on this filing?

Based on this 10-K, Aura Biosciences, Inc. presents a moderate-risk profile. The filing is a standard 10-K, which is a comprehensive annual report, but lacks specific financial performance metrics like revenue or net income in the provided snippet, making a definitive risk assessment challenging without further details.

What should investors do after reading Aura Biosciences, Inc.'s 10-K?

Investors should review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to form a complete investment thesis. The overall sentiment from this filing is neutral.

How does Aura Biosciences, Inc. compare to its industry peers?

Aura Biosciences operates within the biotechnology sector, focusing on the development of biological products.

Are there regulatory concerns for Aura Biosciences, Inc.?

The company is subject to standard SEC regulations for public filings, including the annual 10-K report.

Industry Context

Aura Biosciences operates within the biotechnology sector, focusing on the development of biological products.

Regulatory Implications

The company is subject to standard SEC regulations for public filings, including the annual 10-K report.

What Investors Should Do

  1. Review the full 10-K for detailed financial statements and Management's Discussion and Analysis.
  2. Analyze the company's risk factors section for potential business and financial challenges.
  3. Investigate the details of stock-based compensation and equity offerings mentioned in the filing.

Year-Over-Year Comparison

This is the initial 10-K filing provided in the snippet, so a comparison to a previous filing is not possible.

Filing Stats: 4,474 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-03-27 07:11:34

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 36 Item 1B. Unresolved Staff Comments 84 Item 1C. Cybersecurity 84 Item 2.

Properties

Properties 84 Item 3.

Legal Proceedings

Legal Proceedings 85 Item 4. Mine Safety Disclosures 85 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 86 Item 6. [ Reserved] 86 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 87 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 97 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 97 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 97 Item 9A.

Controls and Procedures

Controls and Procedures 97 Item 9B. Other Information 98 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 98 PART III Item 10. Directors, Executive Officers and Corporate Governance 99 Item 11.

Executive Compensation

Executive Compensation 102 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 109 Item 13. Certain Relationships and Related Transactions, and Director Independence 113 Item 14. Principal Accounting Fees and Services 115 PART IV Item 15. Exhibits, Financial Statement Schedules 117 Item 16. Form 10-K Summary 119

Signatures

Signatures Special Note Regarding Forward-Looking Statements This Form 10-K, or Annual Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", "predicts", "potential", "continue" or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Annual Report include, but are not limited to, statements about: the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs; our ability to efficiently develop our existing product candidates and discover new product candidates; our ability to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates; our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; our abil

B usiness

Item 1. B usiness. Overview We are a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. There is significant unmet need for novel treatments for patients with choroidal melanoma, given the limitations of the current standard of care, or SoC, and patient reluctance to undergo radiotherapy in the form of either plaque brachytherapy or proton beam therapy, both highly-invasive therapies that result in significant vision loss, and potential blindness. Enucleation, or surgical removal of the affected eye is another treatment option for patients with choroidal melanoma, in which patients lose all vision without the possibility of vision restoration. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in our ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Moreover, we intend to assess the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to Bacillus Calmette–Gurin, or BCG, therapy. We believe bel-sar, if approved, has the potential to change the current treatment paradigm for patients with ocular cancers and other solid tumors. Bel-sar has shown clinical benefit and has been generally well-tolerated in clinical trials to date. Interim 12-month results from a Phase 2 trial that evaluated 22 patients in an open label dose escalation study of bel-sar delivered via suprachoroidal, or SC, injection followed by laser light activation was presented at the 2023 American Academy of Ophthalmology. The results demonstrated that patients who received thre

View on Read The Filing